MARKET DEFINITION

When a biological molecule or gene is used to precisely and effectively evaluate pharmaceutical reactions, pathogenic processes, and biological processes, it is referred to be a biomarker. Biomarkers are molecules that are found in tissue, different body fluids, and blood. They are often referred to as molecular markers or signature molecules. Biomarkers are widely used to track how the body reacts to a given disease or condition treatment. They support medical professionals in diagnosing patient health and selecting effective treatments. The U.S. has approved the use of biomarkers as substitute objectives when developing medicines. Drug Enforcement Agency (FDA).

MARKET DYNAMICS

The increase in chronic diseases including diabetes and cardiovascular issues, unhealthy lifestyles, and cancer patients and research programs all contribute to the market's overall expansion. During the forecast period, the market for rare biomarkers is anticipated to grow more quickly due to factors like the low cost of clinical trials in developing nations, the rising incidence of cancer, and new research initiatives. On the other hand, market growth is anticipated to be constrained by factors like high investment requirements, high treatment costs, and high capital expenditure on equipment. The market for rare biomarkers is also being driven by the increased use of biomarker technologies in drug development and genome mapping investigations, as well as a growing preference for customized treatments.

REPORT SCOPE

The report titled “Global Rare Biomarkers Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Rare Biomarkers market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Rare Biomarkers market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Rare Biomarkers Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

 GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

 

MARKET SEGMENTATION

The Global Rare Biomarkers Market is segmented based on biomarker type, component, specimen type, nucleic acid & other biomolecules, end use, application, and region. Based on biomarker type, the market has been segmented into Diagnostic Biomarker, Monitoring Biomarker, Prognostic Biomarker, Susceptibility Biomarker and Others, whereas based on component, the market comprises Isolation Kits & Reagents, Blood Collection Tubes, Systems and Others. Based on specimen type, the market has been segmented into Serum, Plasma and Others, whereas, the application segmentation includes NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases and Others. Based on end use, the market has been segmented into Research Labs/CROs, Academic Institutes, Diagnostics, Hospitals, Prenatal Clinics and Others.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Rare Biomarkers market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Rare Biomarkers market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Rare Biomarkers market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Rare Biomarkers industry in the past three years.

Key players in the Global Rare Biomarkers Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

·         F. Hoffmann-La Roche Ltd.

·         Thermo Fisher Scientific Inc.

·         Abbott

·         QIAGEN

·         PerkinElmer, Inc.

·         Merck KGaA

·         Bio-Rad Laboratories, Inc.

·         Charles River Laboratories International, Inc.

·         Eurofins Scientific

·         Agilent Technologies, Inc.

·         Siemens

·         Epigenomics AG

·         General Electric

COVID-19 IMPACT ANALYSIS ON GLOBAL RARE BIOMARKERS MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

 

Report Attribute/Metric	Details
Market Size	In USD Million
CAGR	In % (2022-2028)
Base Year	2021
Forecast Period	2022 – 2028
Historical Data	2017 to 2021
Forecast Unit	Value (US$ Mn)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors and Trends
Geographies Covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key Players Analyzed	F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, QIAGEN, PerkinElmer, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Charles River Laboratories International, Inc., Eurofins Scientific, Agilent Technologies, Inc., Siemens, Epigenomics AG and General Electric
Customization & Pricing	Available on Request (10% Customization is Free)

 

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

1.    What is the current size of the global Rare Biomarkers market?

2.    What will be the growth rate of the market over the forecast period?

3.    Who are the key manufacturers/vendors in the Rare Biomarkers market space?

4.    What are the major market opportunities and market risks faced by the market?

5.    What is the impact of COVID-19 on the market?

6.    What are the revenue, sales, and price analysis of the top manufacturers in this market?

7.    What are the key outcomes of Porter's five forces model?

8.    Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

·         The report offers comprehensive data on the Rare Biomarkers market elaborating on the current state and future growth prospects both globally and regionally

·         It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth

·         The report offers deep-dive insights into each market segment and critical factors responsible for its growth

·         The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position

·         The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions

·         Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope

·         The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

 

Chapter 1.  Executive Summary

1.1.   Market Outlook

1.2.   Market Segment Outlook

1.3.   Geography Outlook

1.4.   Absolute $ Opportunity

Chapter 2.  Research Methodology

2.1.   Research Approach

2.2.   Scope, Definition, and Assumptions

2.3.   Data Sources

2.3.1. Secondary Sources

2.3.1.1.         Preliminary Data Mining

2.3.2. Primary Sources

2.3.2.1.         Statistical Model

2.3.2.2.         Data Triangulation

2.3.2.3.         Research Objective

Chapter 3.  Market Outlook

3.1.   Introduction

3.2.   Key Trends

3.2.1. Biomarker Type Trends

3.2.2. Component Trends

3.2.3. Specimen Type Trends

3.2.4. Application Trends

3.2.5. End User Trends

3.3.   Market Dynamics

3.3.1. Market Drivers

3.3.1.1.         Impact Analysis of Market Drivers

3.3.2. Market Restraints

3.3.2.1.         Impact Analysis of Market Restraints

3.3.3. Market Opportunities

3.3.3.1.         Impact Analysis of Market Opportunities

3.3.4. Market Challenges

3.3.4.1.         Impact Analysis of Market Challenges

3.4.   Porter’s Five Forces’ Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of New Entrant

3.4.4. Threat of Substitutes

3.4.5. Competitive Rivalry

3.5.   Value Chain Analysis: Global Rare Biomarkers Market

3.6.   COVID-19 Impact Assessment in Rare Biomarkers Market

3.6.1. Impact Assessment on Global Rare Biomarkers Market

3.6.2. Market Trends and Opportunities in the Covid-19 Landscape

Chapter 4.  Global Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

4.1.   Global Rare Biomarkers Market Share, By Biomarker Type, 2017 - 2028 (USD Million)

4.1.1. Diagnostic Biomarker

4.1.2. Monitoring Biomarker

4.1.3. Prognostic Biomarker

4.1.4. Susceptibility Biomarker

4.1.5. Others

Chapter 5.  Global Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

5.1.   Global Rare Biomarkers Market Share, By Component, 2017 - 2028 (USD Million)

5.1.1. Isolation Kits & Reagents

5.1.2. Blood Collection Tubes

5.1.3. Systems

5.1.4. Others     

Chapter 6.  Global Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

6.1.   Global Rare Biomarkers Market Share, By Specimen Type, 2017 - 2028 (USD Million)

6.1.1. Serum

6.1.2. Plasma

6.1.3. Others

Chapter 7.  Global Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

7.1.   Global Rare Biomarkers Market Share, By Application, 2017 - 2028 (USD Million)

7.1.1. NIPT

7.1.2. Oncology

7.1.3. Transcriptomics

7.1.4. Pharmacogenomics

7.1.5. Transplant Rejection

7.1.6. Population Screening

7.1.7. Cardiovascular Diseases

7.1.8. Others

Chapter 8.  Global Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

8.1.   Global Rare Biomarkers Market Share, By End User, 2017 - 2028 (USD Million)

8.1.1. Research Labs/CROs

8.1.2. Academic Institutes

8.1.3. Diagnostics

8.1.4. Hospitals

8.1.5. Prenatal Clinics

8.1.6. Others

Chapter 9.  Global Rare Biomarkers Market Overview, By Geography, 2017 - 2028 (USD Million)

9.1.   Global Rare Biomarkers Market Share, By Geography, 2017 - 2028 (USD Million)

9.1.1. Market Size and Projections, by Countries, 2017 - 2028 (USD Million)

9.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)

Chapter 10.      North America Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

10.1.  North America Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

10.1.1.   Market size and projections, 2017 - 2028 (USD Million)

10.1.2.   North America Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

10.1.3.   North America Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

10.1.4.   North America Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

10.1.5.   North America Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

10.1.6.   North America Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

10.2.  North America Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

10.2.1.   U.S. Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

10.2.1.1.       U.S. Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

10.2.1.2.       U.S. Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

10.2.1.3.       U.S. Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

10.2.1.4.       U.S. Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

10.2.1.5.       U.S. Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

10.2.2.   Canada Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

10.2.2.1.       Canada Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

10.2.2.2.       Canada Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

10.2.2.3.       Canada Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

10.2.2.4.       Canada Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

10.2.2.5.       Canada Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

10.2.3.   Mexico Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

10.2.3.1.       Mexico Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

10.2.3.2.       Mexico Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

10.2.3.3.       Mexico Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

10.2.3.4.       Mexico Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

10.2.3.5.       Mexico Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

Chapter 11.      Europe Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

11.1.  Europe Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

11.1.1.   Market size and projections, 2017 - 2028 (USD Million)

11.1.2.   Europe Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

11.1.3.   Europe Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

11.1.4.   Europe Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

11.1.5.   Europe Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

11.1.6.   Europe Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

11.2.  Europe Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

11.2.1.   Germany Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

11.2.1.1.       Germany Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

11.2.1.2.       Germany Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

11.2.1.3.       Germany Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

11.2.1.4.       Germany Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.1.5.       Germany Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

11.2.2.   France Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

11.2.2.1.       France Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

11.2.2.2.       France Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

11.2.2.3.       France Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

11.2.2.4.       France Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.2.5.       France Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

11.2.3.   UK Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

11.2.3.1.       UK Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

11.2.3.2.       UK Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

11.2.3.3.       UK Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

11.2.3.4.       UK Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.3.5.       UK Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

11.2.4.   Italy Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

11.2.4.1.       Italy Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

11.2.4.2.       Italy Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

11.2.4.3.       Italy Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

11.2.4.4.       Italy Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.4.5.       Italy Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

11.2.5.   Spain Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

11.2.5.1.       Spain Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

11.2.5.2.       Spain Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

11.2.5.3.       Spain Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

11.2.5.4.       Spain Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.5.5.       Spain Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

11.2.6.   NORDIC Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

11.2.6.1.       NORDIC Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

11.2.6.2.       NORDIC Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

11.2.6.3.       NORDIC Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

11.2.6.4.       NORDIC Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.6.5.       NORDIC Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

11.2.7.   Russia and CIS Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

11.2.7.1.       Russia and CIS Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

11.2.7.2.       Russia and CIS Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

11.2.7.3.       Russia and CIS Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

11.2.7.4.       Russia and CIS Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.7.5.       Russia and CIS Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

11.2.8.   Rest of Europe Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

11.2.8.1.       Rest of Europe Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

11.2.8.2.       Rest of Europe Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

11.2.8.3.       Rest of Europe Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

11.2.8.4.       Rest of Europe Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

11.2.8.5.       Rest of Europe Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

Chapter 12.      Asia Pacific Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

12.1.  Asia Pacific Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

12.1.1.   Market size and projections, 2017 - 2028 (USD Million)

12.1.2.   Asia Pacific Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

12.1.3.   Asia Pacific Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

12.1.4.   Asia Pacific Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

12.1.5.   Asia Pacific Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

12.1.6.   Asia Pacific Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

12.2.  Asia Pacific Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

12.2.1.   India Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

12.2.1.1.       India Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

12.2.1.2.       India Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

12.2.1.3.       India Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

12.2.1.4.       India Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.1.5.       India Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

12.2.2.   China Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

12.2.2.1.       China Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

12.2.2.2.       China Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

12.2.2.3.       China Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

12.2.2.4.       China Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.2.5.       China Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

12.2.3.   Japan Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

12.2.3.1.       Japan Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

12.2.3.2.       Japan Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

12.2.3.3.       Japan Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

12.2.3.4.       Japan Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.3.5.       Japan Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

12.2.4.   ASEAN Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

12.2.4.1.       ASEAN Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

12.2.4.2.       ASEAN Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

12.2.4.3.       ASEAN Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

12.2.4.4.       ASEAN Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.4.5.       ASEAN Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

12.2.5.   South Korea Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

12.2.5.1.       South Korea Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

12.2.5.2.       South Korea Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

12.2.5.3.       South Korea Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

12.2.5.4.       South Korea Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.5.5.       South Korea Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

12.2.6.   Australia Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

12.2.6.1.       Australia Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

12.2.6.2.       Australia Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

12.2.6.3.       Australia Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

12.2.6.4.       Australia Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.6.5.       Australia Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

12.2.7.   Rest of Asia Pacific Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

12.2.7.1.       Rest of Asia Pacific Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

12.2.7.2.       Rest of Asia Pacific Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

12.2.7.3.       Rest of Asia Pacific Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

12.2.7.4.       Rest of Asia Pacific Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

12.2.7.5.       Rest of Asia Pacific Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

Chapter 13.      South America Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

13.1.  South America Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

13.1.1.   Market size and projections, 2017 - 2028 (USD Million)

13.1.2.   South America Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

13.1.3.   South America Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

13.1.4.   South America Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

13.1.5.   South America Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

13.1.6.   South America Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

13.2.  South America Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

13.2.1.   Brazil Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

13.2.1.1.       Brazil Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

13.2.1.2.       Brazil Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

13.2.1.3.       Brazil Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

13.2.1.4.       Brazil Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

13.2.1.5.       Brazil Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

13.2.2.   Argentina Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

13.2.2.1.       Argentina Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

13.2.2.2.       Argentina Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

13.2.2.3.       Argentina Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

13.2.2.4.       Argentina Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

13.2.2.5.       Argentina Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

13.2.3.   Rest of South America Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

13.2.3.1.       Rest of South America Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

13.2.3.2.       Rest of South America Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

13.2.3.3.       Rest of South America Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

13.2.3.4.       Rest of South America Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

13.2.3.5.       Rest of South America Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

Chapter 14.      Middle East & Africa Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

14.1.  Middle East & Africa Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

14.1.1.   Market size and projections, 2017 - 2028 (USD Million)

14.1.2.   Middle East & Africa Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

14.1.3.   Middle East & Africa Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

14.1.4.   Middle East & Africa Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

14.1.5.   Middle East & Africa Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

14.1.6.   Middle East & Africa Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

14.2.  Middle East & Africa Rare Biomarkers Market Overview, By Countries, 2017 - 2028 (USD Million)

14.2.1.   GCC Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

14.2.1.1.       GCC Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

14.2.1.2.       GCC Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

14.2.1.3.       GCC Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

14.2.1.4.       GCC Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

14.2.1.5.       GCC Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

14.2.2.   South Africa Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

14.2.2.1.       South Africa Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

14.2.2.2.       South Africa Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

14.2.2.3.       South Africa Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

14.2.2.4.       South Africa Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

14.2.2.5.       South Africa Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

14.2.3.   Rest of Middle East & Africa Rare Biomarkers Market Overview, 2017 - 2028 (USD Million)

14.2.3.1.       Rest of Middle East & Africa Rare Biomarkers Market Overview, By Biomarker Type, 2017 - 2028 (USD Million)

14.2.3.2.       Rest of Middle East & Africa Rare Biomarkers Market Overview, By Component, 2017 - 2028 (USD Million)

14.2.3.3.       Rest of Middle East & Africa Rare Biomarkers Market Overview, By Specimen Type, 2017 - 2028 (USD Million)

14.2.3.4.       Rest of Middle East & Africa Rare Biomarkers Market Overview, By Application, 2017 - 2028 (USD Million)

14.2.3.5.       Rest of Middle East & Africa Rare Biomarkers Market Overview, By End User, 2017 - 2028 (USD Million)

Chapter 15.      Competitive Landscape

15.1.  Competitive Environment, 2021

15.2.  Strategic Framework

15.2.1.   Partnership/Collaborations/Agreement

15.2.2.   Expansion

15.2.3.   Mergers & Acquisitions

15.2.4.   New Product Development

Chapter 16.      Key Vendor Analysis

16.1.              F. Hoffmann-La Roche Ltd.

16.1.1.       Business Overview

16.1.2.       Product Benchmarking

16.1.3.       Financial Data

16.1.4.       Strategic Overview

16.1.5.       Key Developments

16.1.6.       SWOT Analysis

16.2.              Thermo Fisher Scientific Inc.

16.2.1.       Business Overview

16.2.2.       Product Benchmarking

16.2.3.       Financial Data

16.2.4.       Strategic Overview

16.2.5.       Key Developments

16.2.6.       SWOT Analysis

16.3.              Abbott

16.3.1.       Business Overview

16.3.2.       Product Benchmarking

16.3.3.       Financial Data

16.3.4.       Strategic Overview

16.3.5.       Key Developments

16.3.6.       SWOT Analysis

16.4.              QIAGEN

16.4.1.       Business Overview

16.4.2.       Product Benchmarking

16.4.3.       Financial Data

16.4.4.       Strategic Overview

16.4.5.       Key Developments

16.4.6.       SWOT Analysis

16.5.              PerkinElmer, Inc.

16.5.1.       Business Overview

16.5.2.       Product Benchmarking

16.5.3.       Financial Data

16.5.4.       Strategic Overview

16.5.5.       Key Developments

16.5.6.       SWOT Analysis

16.6.              Merck KGaA

16.6.1.       Business Overview

16.6.2.       Product Benchmarking

16.6.3.       Financial Data

16.6.4.       Strategic Overview

16.6.5.       Key Developments

16.6.6.       SWOT Analysis

16.7.              Bio-Rad Laboratories, Inc.

16.7.1.       Business Overview

16.7.2.       Product Benchmarking

16.7.3.       Financial Data

16.7.4.       Strategic Overview

16.7.5.       Key Developments

16.7.6.       SWOT Analysis

16.8.              Charles River Laboratories International, Inc.

16.8.1.       Business Overview

16.8.2.       Product Benchmarking

16.8.3.       Financial Data

16.8.4.       Strategic Overview

16.8.5.       Key Developments

16.8.6.       SWOT Analysis

16.9.              Eurofins Scientific

16.9.1.       Business Overview

16.9.2.       Product Benchmarking

16.9.3.       Financial Data

16.9.4.       Strategic Overview

16.9.5.       Key Developments

16.9.6.       SWOT Analysis

16.10.            Agilent Technologies, Inc.

16.10.1.    Business Overview

16.10.2.    Product Benchmarking

16.10.3.    Financial Data

16.10.4.    Strategic Overview

16.10.5.    Key Developments

16.10.6.    SWOT Analysis

16.11.            Siemens

16.11.1.    Business Overview

16.11.2.    Product Benchmarking

16.11.3.    Financial Data

16.11.4.    Strategic Overview

16.11.5.    Key Developments

16.11.6.    SWOT Analysis

16.12.            Epigenomics AG

16.12.1.    Business Overview

16.12.2.    Product Benchmarking

16.12.3.    Financial Data

16.12.4.    Strategic Overview

16.12.5.    Key Developments

16.12.6.    SWOT Analysis

16.13.            General Electric

16.13.1.    Business Overview

16.13.2.    Product Benchmarking

16.13.3.    Financial Data

16.13.4.    Strategic Overview

16.13.5.    Key Developments

16.13.6.    SWOT Analysis 

Chapter 17.   Future Outlook of the Market